Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Go back to Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 200.31 +0.35 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.96 | 52 Week High | $333.65 | |||
| Open | $200.57 | 52 Week Low | $223.02 | |||
| Day High | $203.45 | P/E | 25.65 | |||
| Day Low | $200.17 | EPS | $7.81 | |||
| Volume | 327,055 | |||||
| (NASDAQ: IONS) | Delayed: 73.26 -0.56 (0.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $73.82 | 52 Week High | $62.68 | |||
| Open | $73.82 | 52 Week Low | $19.59 | |||
| Day High | $74.35 | P/E | N/A | |||
| Day Low | $72.57 | EPS | $0.00 | |||
| Volume | 1,205,592 | |||||
